Keyword Analysis & Research: sironax

Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
sironax0.71775317

Keyword Research: People who searched sironax also searched

Keyword CPC PCC Volume Score
sironax0.870.7254799
sironax pharma0.040.4755613
sironax aus pty ltd0.60.627952
sironax sir24461.670.3953038
sironax ferroptosis1.490.987127
sironax sarm0.340.3687860
sironax ripk10.120.24716100

Search Results related to sironax on Search Engine

  • SIRONAX

    sironax.com.cn

    https://www.sironax.com.cn/

    WEBAug 2, 2022 · SIRONAX. about us. Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases.

    DA: 36 PA: 31 MOZ Rank: 88

  • Sironax Announces Closing of $200 Million Series B Financing

    sironax.com

    https://www.sironax.com/index.php?m=content&c=index&a=show&catid=21&id=17

    WEBAug 02, 2022. Beijing, August 2, 2022 – Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, today announced the completion of a $200 million Series B financing. The round was led by Gaorong Capital and Yunfeng Capital, with ...

    DA: 65 PA: 24 MOZ Rank: 100

  • Sironax | LinkedIn

    linkedin.com

    https://www.linkedin.com/company/sironax

    WEBSironax | 223 followers on LinkedIn. Transformational therapies for degenerative diseases | Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development...

    DA: 93 PA: 44 MOZ Rank: 83

  • 维泰瑞隆（北京）生物科技有限公司 - SIRONAX

    sironax.com.cn

    https://www.sironax.com.cn/zh-cn/

    WEBAug 2, 2022 · 关于我们. 维泰瑞隆是一家处于临床阶段的生物科技公司，致力于在全球范围内探索和开发用于治疗衰老相关退行性疾病的创新药物。. 自2017年成立以来，维泰瑞隆已经建立起了多元的研发管线，聚焦衰老相关退行性疾病的关键致病机理，包括细胞程序性死亡 ...

    DA: 22 PA: 23 MOZ Rank: 70

  • Sironax Announces Closing of $200 Million Series B Financing

    prnewswire.com

    https://www.prnewswire.com/news-releases/sironax-announces-closing-of-200-million-series-b-financing-301597599.html

    WEBBEIJING, Aug. 2, 2022 /PRNewswire/ -- Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative...

    DA: 66 PA: 41 MOZ Rank: 52

  • Chinese biotech Sironax raises $200m for RIPK1 pipeline

    pharmaphorum.com

    https://pharmaphorum.com/news/chinese-biotech-sironax-raises-200m-for-ripk1-pipeline

    WEBAug 3, 2022 · News. Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for...

    DA: 22 PA: 44 MOZ Rank: 6

  • Sironax - Crunchbase Company Profile & Funding

    crunchbase.com

    https://www.crunchbase.com/organization/sironax

    WEBSironax is a clinical-stage biotechnology company that develops novel products and treatments for age-related degenerative diseases. The company is focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation.

    DA: 11 PA: 90 MOZ Rank: 32

  • X-Chem and Sironax Begin Neurodegenerative Disease Drug …

    x-chemrx.com

    https://www.x-chemrx.com/about/news/x-chem-and-sironax-begin-neurodegenerative-disease-drug-discovery-research-partnership/

    WEBWALTHAM, Mass.; Jan. 5, 2023 (Business Wire) — X-Chem (X-Chem), the global leader in DNA-encoded library (DEL) technology, today announces the establishment of a research partnership with Sironax, in which X-Chem will leverage its powerful DEL platform to support Sironax’s drug discovery pipeline.

    DA: 90 PA: 80 MOZ Rank: 57

  • COMPANY NEWS - SIRONAX

    sironax.com

    https://www.sironax.com/index.php?m=content&c=index&a=lists&catid=21

    WEBAug 2, 2022 · Sironax Announces Closing of $200 Million Series B Financing. 维泰瑞隆,SIRONAX,北京维泰瑞隆,生物科技有限公司,退行性疾病,退行性神经疾病,老年痴呆,变革性疗法.

    DA: 99 PA: 21 MOZ Rank: 23

  • SIR-9900 by Sironax for Neurodegenerative Diseases: Likelihood …

    pharmaceutical-technology.com

    https://www.pharmaceutical-technology.com/data-insights/sir-9900-sironax-neurodegenerative-diseases-likelihood-of-approval/

    WEBFeb 29, 2024 · Sironax overview. Sironax is a pharmaceuticals and healthcare company discovering transformational therapies to degenerative disease patients. The company is headquartered in Beijing City, Beijing, China. For a complete picture of SIR-9900’s drug-specific PTSR and LoA scores, buy the report here. This content was updated on 20 …

    DA: 36 PA: 69 MOZ Rank: 80